MAZE - Company ID 0001842295
Maze Therapeutics, Inc. trades as MAZE and has a market capitalization of $1.80 B, making it the #2229 largest US-listed company by market value. This page tracks Maze Therapeutics, Inc. through 161 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-27 |
| Major company event | 8-K | 2026-05-22 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider sale notice | 144 | 2026-05-15 |
| EFFECT | - | 2026-05-13 |
| Quarterly report | 10-Q | 2026-05-12 |
| Major company event | 8-K | 2026-05-12 |
The largest companies sharing Maze Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Maze Therapeutics, Inc. (MAZE) has a market capitalization of $1.80 B as of 2026-07-09, ranking #2229 among US-listed companies.
In its latest fiscal year Maze Therapeutics, Inc. reported a net loss of $131.12M.